Abstract:OBJECTIVE:Hepatic stellate cells (HSCs) transdifferentiation and subsequent inflammation are important pathological processes involved in the formation of cirrhotic portal hypertension. This study characterizes the pathogenetic mechanisms leading to cholestatic liver fibrosis and portal hypertension, and focuses on mammalian target of rapamycin (mTOR) pathway as a potential modulator in the early phase of cirrhotic portal hypertension.METHODS:Early cirrhotic portal hypertension was induced by bile duct ligation (BDL) for three weeks. One week after operation, sham-operated (SHAM) and BDL rats received rapamycin (2 mg/kg/day) by intraperitoneal injection for fourteen days. Vehicle-treated SHAM and BDL rats served as controls. Fibrosis, inflammation, and portal pressure were evaluated by histology, morphometry, and hemodynamics. Expressions of pro-fibrogenic and pro-inflammatory genes in liver were measured by RT-PCR; alpha smooth muscle actin (α-SMA) and antigen Ki67 were detected by immunohistochemistry; expressions of AKT/mTOR signaling molecules, extracellular-signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, and interleukin-1 beta (IL-1β) were assessed by western blot.RESULTS:The AKT/mTOR signaling pathway was markedly activated in the early phase of cirrhotic portal hypertension induced by BDL in rats. mTOR blockade by rapamycin profoundly improved liver function by limiting inflammation, fibrosis and portal pressure. Rapamycin significantly inhibited the expressions of phosphorylated 70KD ribosomal protein S6 kinase (p-P70S6K) and phosphorylated ribosomal protein S6 (p-S6) but not p-AKT Ser473 relative to their total proteins in BDL-Ra rats. Those results suggested that mTOR Complex 1 (mTORC1) rather than mTORC2 was inhibited by rapamycin. Interestingly, we also found that the level of p-ERK1/2 to ERK1/2 was significantly increased in BDL rats, which was little affected by rapamycin.CONCLUSIONS:The AKT/mTOR signaling pathway played an important role in the early phase of cirrhotic portal hypertension in rats, which could be a potential target for therapeutic intervention in the early phase of such pathophysiological progress.

Rapamycin Ameliorates Inflammation and Fibrosis in the Early Phase of Cirrhotic Portal Hypertension in Rats Through Inhibition of Mtorc1 but Not Mtorc2.

Therapeutic Effect of Mtor Inhibitor Rapamycin in Early Phase Cirrhotic Portal Hypertension of Rats

Rapamycin inhibits mesenteric neo-angiogenesis in portal hypertensive rats

Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway.

Rapamycin prevents early steps of the development of diabetic nephropathy in rats.

Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis

Rapamycin Inhibits Epithelial-to-mesenchymal Transition of Peritoneal Mesothelium Cells Through Regulation of Rho GTPases.

The Selective Mtorc1, Rather Than Dual Mtorc1/2, Inhibition Confers Liver Protection from Ischemia and Reperfusion Injury.

Experimental study of activation of mtor/p70s6k signaling pathway in liver cirrhotic portal hypertension

Beneficial Effect of Rapamycin on Liver Fibrosis in a Mouse Model (C57bl/6 Mouse)

Rapamycin Inhibits Hepatic Stellate Cell Proliferation in Vitro and Limits Fibrogenesis in an in Vivo Model of Liver Fibrosis

Rapamycin Ameliorates Kidney Fibrosis by Inhibiting the Activation of Mtor Signaling in Interstitial Macrophages and Myofibroblasts

Rapamycin ameliorates CCl4-induced liver fibrosis in mice through reciprocal regulation of the Th17/Treg cell balance.

Comparison of Anti-Peritoneal Fibrotic Effects Between an Mtorc1-Specific Blocker and a PI3K/mTOR Dual-Blocker.

Rapamycin Reverses Pulmonary Artery Smooth Muscle Cell Proliferation in Pulmonary Hypertension.

Protective Role of Rapamycin in Fibrotic Liver Ischemia/Reperfusion Injury (C57bl/6 Mouse)

Effects of Rapamycin on the Liver Regeneration after Partial Hepatectomy in Rats

The in Vitro Effects of Phospholipase D1-mTOR Axis in Liver Fibrogenesis.

Inhibition of Mtor Attenuates Store-Operated Ca2+ Entry in Cells from Endarterectomized Tissues of Patients with Chronic Thromboembolic Pulmonary Hypertension

Rapamycin Protection of Livers from Ischemia and Reperfusion Injury is Dependent on Both Autophagy Induction and Mammalian Target of Rapamycin Complex 2-Akt Activation

Rapamycin Attenuates Atrial Fibrosis in 5/6 Nephrectomized Rats by Inhibiting Mammalian Target of Rapamycin and Profibrotic Signaling